Science & Technology

Immunomodulatory AVM0703 to bridge Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients to CAR-T cell immunotherapy

Department of Health and Human Services — National Institutes of Health

Opportunity #: 1R44CA310370-01

Award Ceiling

$992K

Award Floor

$992K

Close Date

Aug 31, 2027

534 days left

Total Funding

$992K

Expected Awards

Posted Date

Sep 8, 2025

Cost Sharing Required

Grants.gov ID

sbir-1R44CA310370-01

Description

SBIR Phase Phase II award: "Immunomodulatory AVM0703 to bridge Relapsed/Refractory Diffuse Large B-Cell Lymphoma patients to CAR-T cell immunotherapy" awarded to AVM BIOTECHNOLOGY, INC. in SEATTLE, Washington. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $992,425. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.

Eligible Applicants

Small businesses, Women-owned businesses

Apply on Grants.gov

Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.

View on Grants.gov

Disclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.